Why Edwards Lifesciences (EW) Stock Is Falling Today

Edwards Lifesciences (EW) is down 3.5% today. Here is some analysis on what might have caused this price movement. ([edwards.com](https://www.edwards.com/newsroom/news/2026-10-07-edwards-lifesciences-to-host-earnings-conference-c-ce9e627))

Analysis: There does not appear to be a single clearly negative company announcement tied to today’s move. This could be because investors are taking profits and turning more cautious ahead of the company’s November 4, 2026 earnings report and November 2 investor event, while a recent shift to a Hold rating also may have weighed on sentiment. ([edwards.com](https://www.edwards.com/newsroom/news/2026-10-07-edwards-lifesciences-to-host-earnings-conference-c-ce9e627))

Details:

On October 7, 2026, the company said it will report third-quarter results after the market closes on November 4, 2026. ([edwards.com](https://www.edwards.com/newsroom/news/2026-10-07-edwards-lifesciences-to-host-earnings-conference-c-ce9e627))

On October 5, 2026, the company announced an investor event tied to TCT on November 2, including a live Q&A with physicians and management. ([edwards.com](https://www.edwards.com/newsroom/news/2026-10-05-edwards-lifesciences-to-host-investor-event-in-con))

On October 1, 2026, the company announced FDA approval for its AUTUS size-adjustable pulmonary valve for pediatric patients, so today’s weakness does not seem to stem from an obvious negative product update. ([edwards.com](https://www.edwards.com/newsroom/news/2026-10-01-edwards-lifesciences-receives-fda-approval-for-aut))

A recent analyst note tracked by the market showed a move to Hold, which may have added pressure to a stock already facing a wait-for-earnings setup. ([marketbeat.com](https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-downgrades-edwards-lifesciences-nyse-ew-to-hold-2026-09-26/?utm_source=openai))

Sources:

Edwards Lifesciences, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EW Insider Trading Activity

$EW insiders have traded $EW stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 3 sales selling 41,113 shares for an estimated $3,472,871.
DAVEEN CHOPRA (CVP, TMTT, Surgical & IHFM) has made 0 purchases and 3 sales selling 33,300 shares for an estimated $3,021,344.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 13,000 shares for an estimated $1,040,544.
WAYNE MARKOWITZ (CVP, JAPAC) has made 0 purchases and 3 sales selling 11,014 shares for an estimated $944,962.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 8 sales selling 5,134 shares for an estimated $444,941.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 2 sales selling 3,443 shares for an estimated $291,116.
ANNETTE BRULS (CVP, EMEACLA) sold 2,644 shares for an estimated $237,907
ANDREW M. DAHL (SVP, Corporate Controller) has made 0 purchases and 2 sales selling 1,111 shares for an estimated $98,386.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$EW Hedge Fund Activity

We have seen 589 institutional investors add shares of $EW stock to their portfolio, and 571 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 22,783,175 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,060,966,010
JENNISON ASSOCIATES LLC removed 12,827,871 shares (-98.2%) from their portfolio in Q2 2026, for an estimated $1,160,409,210
ARISTOTLE CAPITAL MANAGEMENT, LLC added 8,665,712 shares (+inf%) to their portfolio in Q2 2026, for an estimated $783,900,307
BLACKROCK, INC. added 6,198,500 shares (+11.8%) to their portfolio in Q2 2026, for an estimated $560,716,310
FMR LLC removed 6,067,821 shares (-41.8%) from their portfolio in Q2 2026, for an estimated $548,895,087
ALLIANCEBERNSTEIN L.P. added 5,193,061 shares (+149.8%) to their portfolio in Q2 2026, for an estimated $469,764,298
WELLINGTON MANAGEMENT GROUP LLP removed 5,183,134 shares (-23.5%) from their portfolio in Q2 2026, for an estimated $468,866,301

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$EW Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $EW, check out Quiver Quantitative's $EW forecast page.

$EW Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 10 analysts offer price targets for $EW in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $110.0 on 07/08/2026
Vijay Kumar from Evercore ISI Group set a target price of $100.0 on 07/06/2026
Marie Thibault from BTIG set a target price of $110.0 on 06/30/2026
Shagun Singh from RBC Capital set a target price of $100.0 on 06/16/2026
Joshua Jennings from TD Cowen set a target price of $104.0 on 06/02/2026
Matt Miksic from Barclays set a target price of $110.0 on 04/27/2026
David Rescott from Baird set a target price of $87.0 on 04/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.